you are being redirected

You will be redirected to the website of our parent company, Schönherr Rechtsanwälte GmbH :

08 May 2024
press release

Austria/Czech Republic: Schoenherr advises on sale of VAMED's rehabilitation business

Schoenherr advised the seller on the sale of the VAMED Group's rehabilitation clinics to PAI-Partners, a French private equity company. The sold rehabilitation business comprises 67 facilities with 9,100 beds and around 9,500 employees in Germany, Austria, Switzerland, the Czech Republic and the UK.

The VAMED Group is part of the Fresenius Group, a German listed medical technology and healthcare group and one of the largest private hospital operators in Germany. VAMED itself is a leading global provider of healthcare services for hospitals and other healthcare facilities. Its services range from the development and planning of infrastructure projects in the healthcare sector, including turnkey construction, maintenance and the overall technical, commercial and infrastructural management of healthcare facilities, through to patient care.

Schoenherr advised on all corporate/M&A aspects of this transaction on a local level (lead: Latham & Watkins) as well as the usual other areas of law. The Schoenherr team was led by Sascha Hödl (partner) and further consisted of Zurab Simonishvili (attorney at law), Joseph Moser (attorney at law), Gabriel Ebner (attorney at law), Constantin Benes (partner), Vladimír Čížek (partner), Christoph Haid (partner), Miriam Simsa (partner), Marco Thorbauer (partner), Teresa Waidmann (partner), Michal Jendzelovsky (counsel), Helena Hangler (counsel), Johannes Stalzer (counsel), Petr Korál (attorney at law), Jiri Marek (attorney at law), Sebastian Müller (attorney at law), Stefanie Orator-Saghy (attorney at law), Alexander Pabst (attorney at law), Felix Schneider (attorney at law), Stefan Dietrich, (associate), Markus Fasching (associate), Stefan Holub (associate), Nikolaus Stepan (associate), Florian Terharen (associate), Carina Fürnkranz (associate), Felix Löwit (associate), Hanna Elisabeth Kirschner (associate), Kerstin Stritzke (associate) and Florian Weisgram (associate).

The transaction documentation is subject to conditions precedent and closing is expected in Q3/Q4 2024.